Lipid Nanoparticle Manufacturing Market: Services and Technologies, 2023-2035 - Distribution by Type of Lipid Nanoparticle (Solid Lipid Nanoparticles and Nanostructured Lipid Carriers), Type of Molecule Delivered (Nucleic Acids, Small Molecules, Proteins/Peptides and Others), Company Size (Very Large and Large, Mid-sized and Small), Target Therapeutic Area (Infectious Diseases, Oncological Disorders, Blood Disorders, Rare Diseases and Other Disorders), Type of End-user (Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, and Other End-users) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts
North America Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
Middle East & Africa Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
South & Central America Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
Liquid Biopsy Market (4th Edition), 2018-2022 (Historical Trends) and 2023-2035 (Forecasted Estimates): Distribution by Application (Early Cancer Diagnosis, Patient Monitoring, Treatment Selection, Recurrence Monitoring and Others), Target Disease Indication (Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastric Cancer, Lung Cancer, Prostate Cancer and Others), Type of Circulating Biomarker (Cell Free DNA, Cell Free RNA, Circulating Tumor DNA, Extracellular Vesicles and Others Circulating Biomarkers), Type of Sample (Blood / Plasma and Others), End users (Hospitals, Research Institutes and Others), Stage of Development (Launched and Under Development), Type of Product (Assay kits, Devices, Software/ Algorithms and others), Type of Technique (Polymerase Chain Reaction, Next Generation Sequencing and Others), Application Area ( Clinical use, Research use only) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World): Industry Trends and Global Forecasts, 2023-2035
South & Central America Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type (Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers), Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others); Source (Nuclear Reactors and Cyclotrons), Application (Targeted Therapeutic [Rx] and Companion Diagnostic [CDx]); Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)
Middle East & Africa Radiopharmaceutical Theranostics Market Forecast to 2028 - Regional Analysis - by Product Type (Alpha Emitters, Beta Emitters, and Positron Emission Tomography (PET) Tracers), Radioisotope (Technetium-99, Gallium-68, Iodine-131, Iodine-123, Fluorine-18 (18F), Yttrium 90 (Y-90), Lutetium (Lu) 177, Copper (Cu) 67, Copper (Cu) 64, and Others); Source (Nuclear Reactors and Cyclotrons), Application (Targeted Therapeutic [Rx] and Companion Diagnostic [CDx]); Indication (Oncology, Cardiology, Neurology, and Others), and End User (Hospitals, Diagnostic Imaging Centers, Academic and Research Institutes, and Others)
Asia Pacific Immunodiagnostics Market Forecast to 2030 - Regional Analysis - by Product (Enzyme-Linked Immunosorbent Assays (ELISA), Chemiluminescence Immunoassays (CLIA), Radioimmunoassays (RIA), and Others), By Clinical Indication (Infectious Diseases, Hepatitis+HIV, Endocrinology, Gastrointestinal, Metabolics, and Others), and End User (Hospitals, Clinics, Diagnostic Laboratories, Academic & Research Institutes, and Others)
Precision Medicine Market Size, Share & Trends Analysis Report By Application ((Diagnostics (Genetic Tests, Esoteric Tests), Therapeutics (Pharmaceuticals, Medical Devices)), By End Use, By Region, And Segment Forecasts, 2023 - 2030
精密医療市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の精密医療市場規模は、2023年から2030年にかけて年平均成長率10.7%で成長し、2030年には1,607億8,000万米ドルに達すると予測されている。費用対効果の高いゲノム・分子生物学的検査法の導…
miRNA Sequencing And Assay Market Size, Share & Trends Analysis Report By Product & Service (Library Preparation Kits), By Technology, By Workflow, By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030
miRNAシーケンスとアッセイ市場の成長と動向
Grand View Research, Incの最新レポートによると、世界のmiRNAシーケンスおよびアッセイ市場規模は、2023年から2030年にかけて13.3%のCAGRを記録し、2030年までに8億2350万米ドルに達すると予測されている。例えば、miRNAは、癌…
Oncology Biomarkers Global Market Report 2023Including: 1) By Biomarker Type: Protein Biomarkers; Genetic Biomarkers2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay; Bioinformatics3) By Cancer Type: Breast Cancer; Lung Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Leukemia; Ovarian Cancer; Liver Cancer4) By Application: Diagnostics; Research And Development; Prognostics; Risk Assessment5) By End-User: Hospitals; Academic And Cancer Research Institutes; Ambulatory Surgical Centers; Diagnostic LaboratoriesCovering: F Hoffmann-La Roche AG; Novartis AG; Thermo Fisher Scientific Inc.; Abbott Laboratories; Eli Lilly and Company